Literature DB >> 22504916

New perspectives in the therapy of chronic hepatitis B.

Pietro Lampertico1, Yun Fan Liaw.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22504916     DOI: 10.1136/gutjnl-2012-302085

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  16 in total

Review 1.  Antiviral therapies and prospects for a cure of chronic hepatitis B.

Authors:  Fabien Zoulim; David Durantel
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

Review 2.  Global strategies are required to cure and eliminate HBV infection.

Authors:  Peter Revill; Barbara Testoni; Stephen Locarnini; Fabien Zoulim
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-24       Impact factor: 46.802

3.  Asymmetric Modification of Hepatitis B Virus (HBV) Genomes by an Endogenous Cytidine Deaminase inside HBV Cores Informs a Model of Reverse Transcription.

Authors:  Smita Nair; Adam Zlotnick
Journal:  J Virol       Date:  2018-04-27       Impact factor: 5.103

Review 4.  Current and future antiviral drug therapies of hepatitis B chronic infection.

Authors:  Lemonica Koumbi
Journal:  World J Hepatol       Date:  2015-05-18

5.  Naturally occurring core protein mutations compensate for the reduced replication fitness of a lamivudine-resistant HBV isolate.

Authors:  Yongmei Zhang; Hu Zhang; Junjie Zhang; Jiming Zhang; Haitao Guo
Journal:  Antiviral Res       Date:  2019-03-19       Impact factor: 5.970

Review 6.  Hepatitis B virus treatment beyond the guidelines: special populations and consideration of treatment withdrawal.

Authors:  Anais Vallet-Pichard; Stanislas Pol
Journal:  Therap Adv Gastroenterol       Date:  2014-07       Impact factor: 4.409

7.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

Authors:  S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao
Journal:  Hepatol Int       Date:  2015-11-13       Impact factor: 6.047

8.  Use of a Fluorescent Analogue of a HBV Core Protein-Directed Drug To Interrogate an Antiviral Mechanism.

Authors:  Smita Nair; Lichun Li; Samson Francis; William W Turner; Michael VanNieuwenhze; Adam Zlotnick
Journal:  J Am Chem Soc       Date:  2018-10-30       Impact factor: 15.419

9.  Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids.

Authors:  Matthew R Campagna; Fei Liu; Richeng Mao; Courtney Mills; Dawei Cai; Fang Guo; Xuesen Zhao; Hong Ye; Andrea Cuconati; Haitao Guo; Jinhong Chang; Xiaodong Xu; Timothy M Block; Ju-Tao Guo
Journal:  J Virol       Date:  2013-04-10       Impact factor: 5.103

10.  Dried blood spot sampling for hepatitis B virus serology and molecular testing.

Authors:  Sofiane Mohamed; Audrey Raimondo; Guillaume Pénaranda; Claire Camus; Denis Ouzan; Sophie Ravet; Marc Bourlière; Hacène Khiri; Patrick Dukan; Daniel Olive; Philippe Halfon
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.